ANTI TUMOR THERAPIES FOR GENIOTURINARY MALIGNANCIES

研究计划：本提案的目标是开发一个生殖泌尿系统 NYPH肿瘤学项目用于治疗泌尿系统肿瘤患者 包括激活最先进的临床试验， 实验室研究，这将增加我们对这些问题的理解， 疾病导致改进的治疗，并指导开始临床医生 在以病人为中心的研究方法上。 具体目标是 1)为肾病患者进行临床和转化试验， 癌症，包括维甲酸脂质体生物疗法的研究 单克隆抗体（mAb）; 2）进行临床试验， 前列腺癌患者的转化试验，包括 识别前列腺特异性膜抗原（PSMA）的mAb muJ 591，以及 脂质体维甲酸对生化（PSA）复发的影响; 3）进行 膀胱癌患者的临床试验，包括 转移性疾病患者或复发风险高的患者 （辅助）;和4）：指导医学肿瘤学研究员和初级教师， 临床和转化试验设计和实施。 该奖项将允许 纳努斯博士保护时间，成功地完成了这些目标。

Research Plan: The objectives of this proposal are to develop a Genitourinary Oncology Program at NYPH for the treatment of patients with urological tumors involving the activation of state of the art clinical trials, performing laboratory-based studies which will increase our understanding of these diseases leading to improved therapies, and to instruct beginning clinicians in the methodologies of patient-oriented research. The specific aims are 1) to conduct clinical and translational trials for patients with renal cancer, including the study of biologic therapies with liposomal tretinoin plus interferon, and monocloncal antibodies (mAb); 2) To conduct clinical and translational trials for patients with prostate cancer, including the study of mAb muJ591 which recognizes prostate specific membrane antigen (PSMA), and the effects of liposomal tretinoin on biochemical (PSA) relapse; 3) To conduct clinical trials for patients with bladder cancer including chemotherapy for patients with metastatic disease or who are at high-risk for relapse (adjuvant); and 4): To mentor medical oncology fellows and junior faculty in clinical and translational trial design and conduct. This award will allow Dr. Nanus protected time to successfully complete these aims.